AAMU
SVA

Amundi Asset Management US’s Sinovac Biotech, Ltd SVA Stock Holding History

Amundi Asset Management US’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,300
Closed -$63K – 1742
2018
Q3 		$63K Hold
8,300
– – ﹤0.01% 1552
2018
Q2 		$62K Hold
8,300
– – ﹤0.01% 1501
2018
Q1 		$71K Buy
8,300
+200
+2% +$1.65K ﹤0.01% 1457
2017
Q4 		$64K Buy
+8,100
New +$60.6K ﹤0.01% 1478

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Amundi Asset Management US's SVA Position: Q4 2018 in Review

Amundi Asset Management US sold out of Sinovac Biotech, Ltd (SVA) in Q4 2018, closing a stake of 8,300 shares — an estimated $63K sold.

Amundi Asset Management US first reported a position in SVA in Q4 2017 and held it in 4 quarters. The position peaked at $71K in Q1 2018. 27 funds tracked by Wall St. Rank hold SVA as of Q4 2018.

  • Amundi Asset Management US reported no remaining Sinovac Biotech, Ltd position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 8,300 Sinovac Biotech, Ltd shares in Q4 2018, an estimated $63K.
  • Amundi Asset Management US first reported a position in Sinovac Biotech, Ltd in Q4 2017 and held it in 4 quarters.
  • Amundi Asset Management US's Sinovac Biotech, Ltd position peaked at $71K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.